Health Law & Business News

Diabetes Crisis Draws Challengers for $22 Billion Insulin Market

May 13, 2019, 11:51 AM

In the hyper-polarized world of U.S. politics, there’s an issue that unites Democrats and Republicans: the high cost of insulin. While millions of Americans with diabetes depend on injections of the hormone that regulates blood sugar, many are skimping on dosages because prices have soared.

At Congressional hearings last month, lawmakers criticized companies for not doing enough to contain prices. The Food and Drug Administration, which is holding a hearing May 13 in Silver Spring, Maryland, on insulin prices, is pushing regulatory reform to create more competition for the three companies that dominate the global $22 billion market: Eli Lilly...

To read the full article log in. To learn more about a subscription click here.